$ATRA
Atara Biotherapeutics, Inc.

2015 Form 10-K Financial Statement

#000156459016014061 Filed on March 04, 2016

View on sec.gov

Income Statement

Concept 2015 2014 Q4 2014
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.83M $5.550M $12.71M
YoY Change 32.42% 238.03%
% of Gross Profit
Research & Development $41.62M $5.050M $15.45M
YoY Change 169.44% 258.71%
% of Gross Profit
Depreciation & Amortization $48.00K $10.00K $6.000K
YoY Change 700.0% 50.0%
% of Gross Profit
Operating Expenses $58.45M $10.60M $28.16M
YoY Change 107.59% 226.83%
Operating Profit -$58.45M -$28.16M
YoY Change 107.59% 226.83%
Interest Expense $1.220M $70.00K $130.0K
YoY Change 838.46% 1200.0%
% of Operating Profit
Other Income/Expense, Net $1.218M $125.0K
YoY Change 874.4% 941.67%
Pretax Income -$57.23M -$10.53M -$28.03M
YoY Change 104.17% 225.83%
Income Tax -$9.000K $0.00 -$25.00K
% Of Pretax Income
Net Earnings -$57.22M -$10.53M -$28.01M
YoY Change 104.32% 219.23%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$2.237M -$2.110M -$5.613M
COMMON SHARES
Basic Shares Outstanding 20.21M
Diluted Shares Outstanding

Balance Sheet

Concept 2015 2014 Q4 2014
SHORT-TERM ASSETS
Cash & Short-Term Investments $320.5M $104.1M $104.1M
YoY Change 207.88% 101.74%
Cash & Equivalents $23.70M $21.90M $21.90M
Short-Term Investments $296.7M $82.20M $82.20M
Other Short-Term Assets $4.100M $1.900M $1.900M
YoY Change 115.79% 850.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $324.6M $106.0M $106.0M
YoY Change 206.23% 104.65% 104.63%
LONG-TERM ASSETS
Property, Plant & Equipment $300.0K $48.00K $0.00
YoY Change 500.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $48.00K $0.00
YoY Change 300.0%
Total Long-Term Assets $400.0K $96.00K $100.0K
YoY Change 300.0% 380.0%
TOTAL ASSETS
Total Short-Term Assets $324.6M $106.0M $106.0M
Total Long-Term Assets $400.0K $96.00K $100.0K
Total Assets $325.0M $106.1M $106.1M
YoY Change 206.31% 104.76% 104.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.400M $440.0K $400.0K
YoY Change 250.0% -27.39% -33.33%
Accrued Expenses $7.700M $1.200M $1.200M
YoY Change 541.67% 300.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.700M $2.724M $2.700M
YoY Change 259.26% 78.74% 80.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $200.0K $216.0K $200.0K
YoY Change 0.0% -6.09% 0.0%
Total Long-Term Liabilities $200.0K $216.0K $200.0K
YoY Change 0.0% -6.09% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.700M $2.724M $2.700M
Total Long-Term Liabilities $200.0K $216.0K $200.0K
Total Liabilities $9.900M $2.940M $2.900M
YoY Change 241.38% 67.62% 61.11%
SHAREHOLDERS EQUITY
Retained Earnings -$40.89M
YoY Change 217.39%
Common Stock $144.2M
YoY Change 6450.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $315.1M $103.2M $103.2M
YoY Change
Total Liabilities & Shareholders Equity $325.0M $106.1M $106.1M
YoY Change 206.31% 104.76% 104.83%

Cashflow Statement

Concept 2015 2014 Q4 2014
OPERATING ACTIVITIES
Net Income -$57.22M -$10.53M -$28.01M
YoY Change 104.32% 219.23%
Depreciation, Depletion And Amortization $48.00K $10.00K $6.000K
YoY Change 700.0% 50.0%
Cash From Operating Activities -$37.16M -$4.960M -$16.63M
YoY Change 123.45% 18.66% 178.56%
INVESTING ACTIVITIES
Capital Expenditures $290.0K -$40.00K $46.00K
YoY Change 530.43% 1433.33%
Acquisitions
YoY Change
Other Investing Activities -$219.8M -$56.90M -$83.32M
YoY Change 163.85%
Cash From Investing Activities -$220.1M -$56.93M -$83.36M
YoY Change 164.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $263.4M $56.46M
YoY Change 366.63%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 259.2M 58.08M 70.27M
YoY Change 268.91% 51.17% 31.64%
NET CHANGE
Cash From Operating Activities -37.16M -4.960M -16.63M
Cash From Investing Activities -220.1M -56.93M -83.36M
Cash From Financing Activities 259.2M 58.08M 70.27M
Net Change In Cash 1.940M -3.810M -29.72M
YoY Change -106.53% -111.13% -162.69%
FREE CASH FLOW
Cash From Operating Activities -$37.16M -$4.960M -$16.63M
Capital Expenditures $290.0K -$40.00K $46.00K
Free Cash Flow -$37.45M -$4.920M -$16.68M
YoY Change 124.57% 17.7% 179.19%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-58448000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
125000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-28156000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
528000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
108000
CY2015Q4 us-gaap Assets
Assets
324975000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-9000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
170000
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-418000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
48000
CY2014Q4 us-gaap Assets
Assets
106122000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
440000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1225000
CY2014Q4 atra Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
824000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
235000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2724000
CY2014Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
216000
CY2015Q4 us-gaap Liabilities
Liabilities
9875000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3921000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
324597000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
270000
CY2015Q4 us-gaap Short Term Investments
ShortTermInvestments
296736000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
194000
CY2014Q4 us-gaap Short Term Investments
ShortTermInvestments
82219000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1910000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
106026000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
48000
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28458807
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
413725000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1445000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28458807
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9709000
CY2015Q4 atra Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
5112000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2624000
CY2015Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
166000
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
1713000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-28006000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3756000
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
965825
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-8773000
CY2013 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-9.08
CY2013 us-gaap Operating Expenses
OperatingExpenses
8615000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-8615000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12000
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8773000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8603000
CY2014 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-100000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28031000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-25000
CY2014 us-gaap Operating Expenses
OperatingExpenses
28156000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1218000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-57230000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-57221000
CY2013 atra Restricted Stock Issued To Related Party In Exchange For Notes Receivable
RestrictedStockIssuedToRelatedPartyInExchangeForNotesReceivable
331000
CY2013 us-gaap Interest Income Related Party
InterestIncomeRelatedParty
4000
CY2013 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
105000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1713000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-11017000
CY2014 us-gaap Interest Income Related Party
InterestIncomeRelatedParty
2000
CY2014 atra Non Cash Research And Development Expenses
NonCashResearchAndDevelopmentExpenses
750000
CY2014 atra Note Receivable From Stockholders Collection Of Stock Subscription
NoteReceivableFromStockholdersCollectionOfStockSubscription
337000
CY2014 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
20000
CY2014 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
70000
CY2014 atra Stock Issued During Period Value For Research And Development Expenses Related To Technology Licensing Option
StockIssuedDuringPeriodValueForResearchAndDevelopmentExpensesRelatedToTechnologyLicensingOption
750000
CY2014 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
74573000
CY2015 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-3465000
CY2014 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-526000
CY2014Q4 us-gaap Liabilities
Liabilities
2940000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-100000
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19692937
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19692937
CY2015 atra Research And Development Expense Excluding Related Party
ResearchAndDevelopmentExpenseExcludingRelatedParty
41618000
CY2014 atra Research And Development Expense Excluding Related Party
ResearchAndDevelopmentExpenseExcludingRelatedParty
14380000
CY2013 atra Research And Development Expense Excluding Related Party
ResearchAndDevelopmentExpenseExcludingRelatedParty
4306000
CY2014 atra Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
1066000
CY2013 atra Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
553000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-57639000
CY2015 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-2.24
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25583334
CY2014 atra Stock Issued During Period Value Net Of Discount And Offering Costs
StockIssuedDuringPeriodValueNetOfDiscountAndOfferingCosts
56456000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10101000
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
80000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
439000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
10251000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
10101000
CY2015 us-gaap Depreciation
Depreciation
48000
CY2014 us-gaap Depreciation
Depreciation
6000
CY2013 us-gaap Depreciation
Depreciation
4000
CY2015 atra Write Off Of Property And Equipment
WriteOffOfPropertyAndEquipment
21000
CY2015 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-94000
CY2014 us-gaap Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
2000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28106000
CY2014 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-5.62
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4985540
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-3727000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
767000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1246000
CY2015 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
61000
CY2014 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
37000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1005000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-164000
CY2015 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1399000
CY2014 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
894000
CY2015 atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
4288000
CY2014 atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
468000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10251000
CY2015 atra Increase Decrease In Long Term Liabilities
IncreaseDecreaseInLongTermLiabilities
29000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-37156000
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5966000
CY2015 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
379776000
CY2013 us-gaap Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
4000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
158000
CY2013 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-27000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
485000
CY2013 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
280000
CY2013 atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
356000
CY2015 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
293000
CY2014 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
4000
CY2013 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
104000
CY2014 atra Increase Decrease In Long Term Liabilities
IncreaseDecreaseInLongTermLiabilities
78000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-16628000
CY2014 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
95525000
CY2015 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
160133000
CY2014 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
12208000
CY2015 atra Transfers To Restricted Cash
TransfersToRestrictedCash
194000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
290000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
46000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-220127000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-83363000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-3000
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
263434000
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
56455000
CY2015 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4647000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
439000
CY2014 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
13481000
CY2013 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
53377000
CY2014 us-gaap Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
337000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
259226000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
70273000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
53377000
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-94000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1849000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-29718000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
47408000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51615000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4207000
CY2014 us-gaap Stock Issued1
StockIssued1
750000
CY2013 atra Issuance Of Convertible Preferred Stock In Exchange For License
IssuanceOfConvertiblePreferredStockInExchangeForLicense
1003000
CY2013 atra Change In Obligation To Issue Convertible Preferred Stock
ChangeInObligationToIssueConvertiblePreferredStock
-1003000
CY2015 atra Issuance Of Common Stock Upon Vesting Of Stock Awards
IssuanceOfCommonStockUponVestingOfStockAwards
80000
CY2014 atra Issuance Of Common Stock Upon Vesting Of Stock Awards
IssuanceOfCommonStockUponVestingOfStockAwards
90000
CY2013 atra Issuance Of Common Stock Upon Vesting Of Stock Awards
IssuanceOfCommonStockUponVestingOfStockAwards
105000
CY2015 atra Change In Other Long Term Liabilities Related To Non Vested Stock Awards
ChangeInOtherLongTermLiabilitiesRelatedToNonVestedStockAwards
-80000
CY2014 atra Change In Other Long Term Liabilities Related To Non Vested Stock Awards
ChangeInOtherLongTermLiabilitiesRelatedToNonVestedStockAwards
-90000
CY2013 atra Change In Other Long Term Liabilities Related To Non Vested Stock Awards
ChangeInOtherLongTermLiabilitiesRelatedToNonVestedStockAwards
226000
CY2015 us-gaap Income Taxes Paid
IncomeTaxesPaid
3000
CY2014 us-gaap Income Taxes Paid
IncomeTaxesPaid
70000
CY2013 us-gaap Income Taxes Paid
IncomeTaxesPaid
22000
CY2015 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Uncertainties </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">We place cash and cash equivalents in the custody of financial institutions that management believes are of high credit quality, which at times, may be in excess of the amount insured by the Federal Deposit Insurance Corporation. We also have short-term investments in money market funds, U.S. Treasury, government agency and corporate debt obligations, commercial paper and asset-backed securities, which can be subject to certain credit risk. However, we mitigate the risks by investing in high-grade instruments, limiting our exposure to any one issuer, and monitoring the ongoing creditworthiness of the financial institutions and issuers. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to certain risks and uncertainties and believe that changes in any of the following areas could have a material adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, our product candidates; performance of third-party clinical research organizations and manufacturers upon which we rely; development of sales channels; protection of our intellectual property; litigation or claims against us based on intellectual property, patent, product, regulatory or other factors; and our ability to attract and retain employees necessary to support our growth. </p></div>
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include the fair value of common stock and the fair value of preferred stock prior to our IPO and estimates related to clinical trial accruals and stock-based compensation expense. Actual results could differ materially from those estimates. </p></div>
CY2014Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
104116000
CY2015 dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
CY2015 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-08-01
CY2014Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.7692
CY2015 us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
Nine-for-one basis
CY2015 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2015 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2015Q4 us-gaap Cash
Cash
1500000
CY2015 atra Cash And Cash Equivalents Maturity Period
CashAndCashEquivalentsMaturityPeriod
P90D
CY2015 atra Investment Maturity Period
InvestmentMaturityPeriod
P90D
CY2015 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2015Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
211311000
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
78649000
CY2015Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
108202000
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
25567000
CY2015Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
319513000
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
104216000
CY2015Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
211059000
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
78611000
CY2015Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
107935000
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
25505000
CY2015Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
318994000
CY2015 atra Cash Paid For Exclusive Option Agreement
CashPaidForExclusiveOptionAgreement
1250000
CY2015 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
59761
CY2015 us-gaap Stock Issued1
StockIssued1
750000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2000000
CY2015 us-gaap License Costs
LicenseCosts
4500000
CY2015Q4 atra Potential Milestone Payments Payable
PotentialMilestonePaymentsPayable
33000000
CY2015Q4 atra Due To Licensors Current And Noncurrent
DueToLicensorsCurrentAndNoncurrent
0
CY2014Q4 atra Due To Licensors Current And Noncurrent
DueToLicensorsCurrentAndNoncurrent
0
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
967000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
969000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
981000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
734000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
614000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
207000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
4472000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000
CY2015Q4 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2014Q4 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2015Q4 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
520000000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4349260
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms
the exercise price of an option granted to a 10% shareholder cannot be less than 110% of the estimated fair value of the shares on the date of grant. Options granted to employees and non-employees generally vest over four years and expire in seven years.
CY2015 atra Shareholder Ownership Percent
ShareholderOwnershipPercent
0.10
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
623936
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2610174
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
23822
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
72759
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3137529
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3137529
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
276909
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.69
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
28.95
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
18.44
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
37.11
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
25.81
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
25.81
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
17.75
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y5M1D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y5M1D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
12978000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
12978000
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2470000
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
600000
CY2015 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2900000
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
100000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
0
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10251000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10101000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1713000
CY2015 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-1000
CY2014 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-36000
CY2013 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
153000
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-8000
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
11000
CY2013 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
17000
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-9000
CY2014 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-25000
CY2013 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
170000
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.006
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.073
CY2013 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.068
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.003
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.001
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.334
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.267
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.288
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.001
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.020
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
24219000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8220000
CY2015Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
5122000
CY2014Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
2279000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4999000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1964000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements
1436000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements
757000
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1249000
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
494000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
37025000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
13714000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
37025000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
13714000
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
23300000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9200000
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2900000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
68800000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
68700000
CY2015 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
Begin to expire in 2032 in various amounts if not utilized.
CY2015Q4 atra Unrealized Net Operating Loss Deductions From Stock Option Exercises
UnrealizedNetOperatingLossDeductionsFromStockOptionExercises
8900000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1014000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
629000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1643000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2671000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4314000
CY2015Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
100000

Files In Submission

Name View Source Status
0001564590-16-014061-index-headers.html Edgar Link pending
0001564590-16-014061-index.html Edgar Link pending
0001564590-16-014061.txt Edgar Link pending
0001564590-16-014061-xbrl.zip Edgar Link pending
atra-10k_20151231.htm Edgar Link pending
atra-20151231.xml Edgar Link completed
atra-20151231.xsd Edgar Link pending
atra-20151231_cal.xml Edgar Link unprocessable
atra-20151231_def.xml Edgar Link unprocessable
atra-20151231_lab.xml Edgar Link unprocessable
atra-20151231_pre.xml Edgar Link unprocessable
atra-ex1029_1043.htm Edgar Link pending
atra-ex211_56.htm Edgar Link pending
atra-ex231_9.htm Edgar Link pending
atra-ex311_7.htm Edgar Link pending
atra-ex312_6.htm Edgar Link pending
atra-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201603042151332511267.jpg Edgar Link pending
g201603042151332831268.jpg Edgar Link pending
g201603042151338761269.jpg Edgar Link pending
g201603042151338921270.jpg Edgar Link pending
g201603042151403241303.jpg Edgar Link pending
g201603042151404341304.jpg Edgar Link pending
g201603042151404491305.jpg Edgar Link pending
g201603042151405901306.jpg Edgar Link pending
g201603042151405901307.jpg Edgar Link pending
g201603042151411211308.jpg Edgar Link pending
g201603042151413401309.jpg Edgar Link pending
g201603042151413401310.jpg Edgar Link pending
g201603042151413551311.jpg Edgar Link pending
g201603042151413871312.jpg Edgar Link pending
g201603042151414341313.jpg Edgar Link pending
g201603042151528971314.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending